{
  "benchmark_id": "34857732_01",
  "sample_system": "",
  "tissue": "Prostate",
  "source_type": "cell_line",
  "perturbation_type": "drug",
  "perturbation_name": "GSK126",
  "default_cell_subset": "",
  "description": "LNCaP prostate cancer cells treated with EZH2 inhibitor GSK126.",
  "smiles": "CCC(C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCNCC4)C(=O)NCC5=C(C=C(NC5=O)C)C)C",
  "test_cases": [
    {
      "test_id": "34857732_01_01",
      "target_genes": [
        "UBE2C",
        "CDK1"
      ],
      "perturb_var": "dose",
      "control": "C",
      "dose_groups": [
        "1.0 uM"
      ],
      "time_groups": [],
      "relation": "DOWN",
      "cell_type": "LNCaP prostate cancer cell line"
    },
    {
      "test_id": "34857732_01_02",
      "target_genes": [
        "KLK3",
        "TMPRSS2",
        "KLK2",
        "ABCC4"
      ],
      "perturb_var": "dose",
      "control": "C",
      "dose_groups": [
        "1.0 uM"
      ],
      "time_groups": [],
      "relation": "UP",
      "cell_type": "LNCaP prostate cancer cell line"
    },
    {
      "test_id": "34857732_01_03",
      "target_genes": [
        "IL13",
        "IL4"
      ],
      "perturb_var": "dose",
      "control": "C",
      "dose_groups": [
        "1.0 uM"
      ],
      "time_groups": [],
      "relation": "NS",
      "cell_type": "LNCaP prostate cancer cell line"
    }
  ]
}